Author(s):
Sinha Debasish, Sharma Tripti
Email(s):
debasishsinha69@gmail.com , triptisharma@soa.ac.in
DOI:
10.5958/0974-360X.2021.00168.2 
Address:
Sinha Debasish1, Sharma Tripti2
1Phyto Pharmaceutical Pvt. Ltd. Jagatpur, Odisha, India.
2School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar-751003, Odisha, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 2,
Year - 2021
ABSTRACT:
Chemokines are small chemotactic cytokines, which play a significant role in the control of cell migration during immune surveillance and inflammation. Chemokines are responsible for the migration of leukocytes to secondary lymphoid organs in addition to tumor growth and metastasis. Thus, inhibition of chemokine receptors attracted attention for the treatment of cancer, inflammatory diseases as well as HIV infections. In this study, a new series of 3-substituted 4-phenylamino coumarin were computationally designed and docked with chemokine receptors (CXCR4). The compounds were screened for drug likeliness using the Lipinski rule of five by Molinspiration server. Structure based protein ligand interaction was performed using PyRx software. Molecular docking results of all the selected coumarin derivatives showed binding affinity with the CXCR4 receptor ranging between -8.0 to -9.7kcal/mol compared with that of the standard drug Plerixafor (-9.2 kcal/mol). Compound 27A and 18B showed higher docking score compared with the standard drug. Analysis of docking results indicated substitutions at C3 position by trifluroacetyl or 4 methoxy phenyl group showed enhanced binding affinity towards CXCR4 receptor. From this study, it is concluded that these screened analogs may serve as potential inhibitors for CXCR4 and they might be promising leads for the development of new therapeutic agents against cancer and its associated complications.
Cite this article:
Sinha Debasish, Sharma Tripti. Molecular Docking studies of 3-substituted 4-phenylamino coumarin derivatives as Chemokine receptor inhibitor. Research J. Pharm. and Tech. 2021; 14(2):943-948. doi: 10.5958/0974-360X.2021.00168.2
Cite(Electronic):
Sinha Debasish, Sharma Tripti. Molecular Docking studies of 3-substituted 4-phenylamino coumarin derivatives as Chemokine receptor inhibitor. Research J. Pharm. and Tech. 2021; 14(2):943-948. doi: 10.5958/0974-360X.2021.00168.2 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-64
REFERENCES:
1. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, De Graaf C, Vischer HF, Leurs R. Pharmacological modulation of chemokine receptor function. British Journal of Pharmacology. 2012; 165(6):1617-1643.
2. Kufareva I, Salanga CL, Handel TM. Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunology and Cell Biology. 2015; 93(4): 372-383.
3. Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Frontiers in Immunology. 2015; 30: (6)12.
4. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry, Cold Spring Harbor Perspectives in Medicine. 2012; 2(8): a006866.
5. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proceedings of the National Academy of Sciences, 1997; 94(5):1925-30.
6. Oberlin E, Amara A, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996; 382(6594): 833-835.
7. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996; 382(6594): 829-833.
8. Saini V, Marchese A, Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. Journal of Biological Chemistry. 2010; 285(20): 15566-76.
9. Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opinion on Biological Therapy. 2008; 8(11): 1797-1804.
10. Salem M, Marzouk M, El-Kazak A. Synthesis and characterization of some new coumarins with in vitro antitumor and antioxidant activity and high protective effects against DNA damage. Molecules. 2016; 21(2): 249-269.
11. Shi Y, Zhou CH. Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents. Bioorganic and Medicinal Chemistry Letters. 2011; 21(3): 956-960.
12. El-Haggar R, Al-Wabli R. Anti-inflammatory screening and molecular modeling of some novel coumarin derivatives. Molecules. 2015; 20(4): 5374-91.
13. Tsay SC, Hwu JR, Singha R, Huang WC, Chang YH, Hsu MH, Shieh FK, Lin CC, Hwang KC, Horng JC, De Clercq E. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. European Journal of Medicinal Chemistry. 2013; 63: 290-298.
14. Leonetti F, Favia A, Rao A, Aliano R, Paluszcak A, Hartmann RW, Carotti A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. Journal of Medicinal Chemistry. 2004; 47(27): 6792-6803.
15. Seidel C, Schnekenburger M, Zwergel C, Gaascht F, Mai A, Dicato M, Kirsch G, Valente S, Diederich M. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic and Medicinal Chemistry Letters. 2014; 24(16): 3797-3801.
16. Jacquot Y, Laïos I, Cleeren A, Nonclercq D, Bermont L, Refouvelet B, Boubekeur K, Xicluna A, Leclercq G, Laurent G. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl) coumarins on human breast carcinoma cells. Bioorganic and Medicinal Chemistry Letters. 2007; 15(6): 2269-82.
17. Neelgundmath M, Dinesh KR, Mohan CD, Li F, Dai X, Siveen KS, Paricharak S, Mason DJ, Fuchs JE, Sethi G, Bender A. Novel synthetic coumarins that targets NF-κB in hepatocellular carcinoma. Bioorganic and Medicinal Chemistry Letters. 2015; 25(4): 893-897.
18. Benci K, Mandić L, Suhina T, Sedić M, Klobučar M, Kraljević Pavelić S, Pavelić K, Wittine K, Mintas M. Novel coumarin derivatives containing 1, 2, 4-triazole, 4, 5-dicyanoimidazole and purine moieties: Synthesis and evaluation of their cytostatic activity. Molecules. 2012; 17(9): 11010-11025.
19. Bana E, Sibille E, Valente S, Cerella C, Chaimbault P, Kirsch G, Dicato M, Diederich M, Bagrel D. A novel coumarin‐quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. Molecular Carcinogenesis. 2015; 54(3): 229-241.
20. Kini SG, Choudhary S, Mubeen M. Synthesis, docking study and anticancer activity of coumarin substituted derivatives of benzothiazole. Journal of Computational Methods in Molecular Design. 2012; 2(1): 51-60.
21. Mirunalini S, Deepalakshmi K, Manimozhi J. Antiproliferative effect of coumarin by modulating oxidant/antioxidant status and inducing apoptosis in Hep2 cells. Biomedicine and Aging Pathology. 2014; 4(2): 131-135.
22. Luo G, Muyaba M, Lyu W, Tang Z, Zhao R, Xu Q, You Q, Xiang H. Design, synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin derivatives as antitumor agents. Bioorganic and Medicinal Chemistry Letters. 2017; 27(4): 867-874.
23. Sharma T. Insilico docking approach to study the binding affinity of isoflavones on the crystal structure of estrogen receptor alpha. Indian Drugs. 2017; 54(10): 7-15.
24. Purushothaman B, Suganthi N, Jothi A, Shanmugam K. Molecular Docking Studies of potential anticancer agents from Ocimum basilicum L. against human colorectal cancer regulating genes: An insilico approach. Research Journal of Pharmacy and Technology. 2019; 12(7):3423-7.
25. Kumar L, Verma R. Molecular docking based approach for the design of Novel Flavone Analogues as inhibitor of Beta-Hydroxyacyl-ACP Dehydratase HadAB complex. Research Journal of Pharmacy and Technology. 2017; 10(8):2439-45.
26. Kawatkar SP, Yan M, Gevariya H, Lim MY, Eisold S, Zhu X, Huang ZJ. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists, Experimental Biology and Medicine. 2011; 236(7): 844-850.
27. Neves MA, Simões S, Melo ML. Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach. Journal of Computer-Aided Molecular Design. 2010; 24(12): 1023-1033.
28. Lam AR, Bhattacharya S, Patel K, Hall SE, Mao A, Vaidehi N. Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4. Journal of Chemical Information and Modelling. 2010; 51(1): 139-147.